Nuo Therapeutics, Inc. (AURX)
OTCMKTS · Delayed Price · Currency is USD
1.020
0.00 (0.00%)
Jul 27, 2026, 1:09 PM EST
Nuo Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.26 | 0.55 | 0.28 | 0.93 | 2.05 | 1.41 |
Cash & Short-Term Investments | 0.26 | 0.55 | 0.28 | 0.93 | 2.05 | 1.41 |
Cash Growth | 374.04% | 93.49% | -69.45% | -54.73% | 45.01% | 776.26% |
Accounts Receivable | 0.87 | 0.56 | 0.25 | 0.25 | 0.09 | - |
Receivables | 0.87 | 0.56 | 0.25 | 0.25 | 0.09 | - |
Inventory | 0.25 | 0.21 | 0.15 | 0.21 | 0.24 | - |
Prepaid Expenses | 0.13 | 0.06 | 0.16 | 0.17 | 0.2 | 0.05 |
Restricted Cash | - | - | - | - | 0.06 | - |
Total Current Assets | 1.52 | 1.38 | 0.84 | 1.56 | 2.63 | 1.47 |
Property, Plant & Equipment | 0.43 | 0.47 | 0.35 | 0.31 | 0.41 | - |
Total Assets | 1.95 | 1.85 | 1.19 | 1.88 | 3.05 | 1.47 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.39 | 0.44 | 0.22 | 0.39 | 0.4 | 0.53 |
Accrued Expenses | 0.59 | 0.49 | 0.29 | 0.19 | 0.12 | 0.15 |
Current Portion of Leases | 0.08 | 0.08 | 0.07 | 0.09 | 0.08 | - |
Current Unearned Revenue | 0.31 | 0.3 | - | - | - | - |
Total Current Liabilities | 1.37 | 1.31 | 0.58 | 0.67 | 0.6 | 0.67 |
Long-Term Debt | 1.03 | 0.5 | - | - | - | - |
Long-Term Leases | - | 0.02 | 0.1 | 0.16 | 0.26 | - |
Long-Term Unearned Revenue | 0.94 | 0.98 | - | - | - | - |
Other Long-Term Liabilities | - | - | - | - | -0 | - |
Total Liabilities | 3.33 | 2.8 | 0.68 | 0.84 | 0.86 | 0.67 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 34 | 33.81 | 32.77 | 30.97 | 28.95 | 24.38 |
Retained Earnings | -35.39 | -34.77 | -32.26 | -29.94 | -26.76 | -23.59 |
Total Common Equity | -1.38 | -0.96 | 0.51 | 1.04 | 2.19 | 0.79 |
Shareholders' Equity | -1.38 | -0.96 | 0.51 | 1.04 | 2.19 | 0.79 |
Total Liabilities & Equity | 1.95 | 1.85 | 1.19 | 1.88 | 3.05 | 1.47 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.1 | 0.6 | 0.16 | 0.26 | 0.34 | - |
Net Cash (Debt) | -0.84 | -0.05 | 0.12 | 0.67 | 1.72 | 1.41 |
Net Cash Growth | - | - | -82.25% | -60.78% | 21.32% | 776.26% |
Net Cash Per Share | -0.02 | -0.00 | 0.00 | 0.02 | 0.04 | 0.05 |
Filing Date Shares Outstanding | 48.41 | 48.29 | 46.82 | 44.24 | 41.8 | 37.12 |
Total Common Shares Outstanding | 48.29 | 48.18 | 46.82 | 44.24 | 41.8 | 37.12 |
Working Capital | 0.15 | 0.07 | 0.26 | 0.89 | 2.03 | 0.79 |
Book Value Per Share | -0.03 | -0.02 | 0.01 | 0.02 | 0.05 | 0.02 |
Tangible Book Value | -1.38 | -0.96 | 0.51 | 1.04 | 2.19 | 0.79 |
Tangible Book Value Per Share | -0.03 | -0.02 | 0.01 | 0.02 | 0.05 | 0.02 |
Machinery | 0.89 | 0.88 | 0.61 | 0.45 | 0.45 | 0.39 |